Reduced Intensity Conditioning Allogeneic Transplantation for CLL With Preemptive MDR Management (ICLL 03 RICAC-PMM)

Trial Profile

Reduced Intensity Conditioning Allogeneic Transplantation for CLL With Preemptive MDR Management (ICLL 03 RICAC-PMM)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Fludarabine (Primary) ; Haematopoietic stem cell therapy (Primary) ; Antithymocyte globulin; Busulfan
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms RICAC
  • Most Recent Events

    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting, as per an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Preliminary results (n=30) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 20 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top